Cardiff Oncology Inc logo

CRDF

Cardiff Oncology Inc

$2.59

Earnings Summary

Net Profits
$-10.45Mn

Highlights

Net Profits:

Cardiff Oncology Inc’s net profit fell -54.64% since last year same period to $-10.45Mn in the Q2 2022. On a quarterly growth basis, Cardiff Oncology Inc has generated 4.95% jump in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Cardiff Oncology Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.25
EPS Estimate Current Year
-0.25

Highlights

EPS Estimate Current Quarter:

Cardiff Oncology Inc’s earning per share (EPS) estimates for the current quarter stand at -0.25 - a -8.7% fall from last quarter’s estimates.

EPS Estimate Current Year:

Cardiff Oncology Inc’s earning per share (EPS) estimates for the current year stand at -0.25.

Key Ratios

Key ratios of the Cardiff Oncology Inc post its Q2 2022 earnings

Return on Assets (ROA)
-0.17
Return on Equity (ROE)
-0.29
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Cardiff Oncology Inc’s return on assets (ROA) stands at -0.17.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Cardiff Oncology Inc’s return on equity (ROE) stands at -0.29.

Dividend Per Share (DPS):

Cardiff Oncology Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.23
-0.25
-8.7%

Company Information

Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Its goal is to overcome resistance, improve response to treatment and increase overall survival. The company is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. Cardiff has three clinical programs that have demonstrated the safety and efficacy of onvansertib: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® (bevacizumab) in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga® (abiraterone)/prednisone in metastatic castration-resistant prostate cancer (mCRPC); and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML). A new Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin and fluorouracil for the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC) is planned for initiation in the first half of 2021.

Organisation
Cardiff Oncology Inc
Headquarters
San Diego, California, US
Employees
12
Industry
Health Services
CEO
Mark Erlander